BARCELONA – 01-15-2020 (PRDistribution.com) —
The research, currently underway both in the United States of America and Europe, will involve an investment of more than $10 million
The worldwide launch of the new medicament to treat this type of external otitis, expected for the end of 2021, reinforces Salvat’s positioning in otology at an international level
The company’s international business represents more than 45% of its revenues
Barcelona, January 2020 – Salvat, a Spanish laboratory that manufactures products such as Cristalmina, Monolitum, Relive, Levogastrol and Cetraxal, expects the approval and launch of the first topical medicament for the treatment of otomycosis in just over a year in USA and Europe. This commitment reinforces Salvat’s position as a world leader in the field of otology.
Clinical trials, agreed with the FDA, began at the end of 2019 and are scheduled to end this year. These studies will include 400 adult patients affected by otomycosis, mainly from hospitals in the US and Spain and with the participation of other countries such as Mexico, Portugal, Bulgaria and Romania.
For Alberto Bueno, Salvat’s General Manager, “this project is a reflection of the firm R&D commitment we have made in the area of otology, and reinforces our leadership position in this therapeutic area, without losing focus on other areas of strategic growth for Salvat. Only in 2019, we have invested 10 million dollars in R&D, which represents 15% of our whole turnover”.
Otomycosis is a type of external otitis caused by an acute fungal infection that affects the ear canal. It is estimated that approximately 10% of people living in developed countries suffer from at least one episode of this kind of otitis in their lifetime[i].
This medicament in development is a major advance in the treatment of otomycosis. It is hoped that, thanks to its topical and localized application, it will become a more effective solution to otomycosis, which currently has no approved treatment.
In the regard of the expansion of the Pharmaloop plant in Alcalá de Henares (Spain), it is expected to be complete by 2020, which will have involved an investment of more than 35 million euros and the creation of more than 100 jobs.
Laboratorios Salvat, pioneer in Otolaryngology
Otorhinolaryngologist recognize Salvat as the number one company in the development of treatments for otology. This new medicament for the treatment of otomycosis confirms Salvat’s commitment to this medical speciality and the company’s desire to consolidate its leadership in the treatment of ear diseases.
Since its foundation in 1955, LaboratoriosSalvat, an independent private capital company owned by the Peris family, has been working to improve the quality of life of people through innovation. developing high added-value medicines and healthcare products. Besides its own sales structure in Spain and Portugal and through commercial partners in the rest of the world, Salvat has a subsidiary in the United States, Salvat USA, Inc. from which it manages its international expansion.
Salvat’s growing production capacity includes a sterile liquid production line (Blow-Fill-Seal technology) located in the United States to supply the American market, and the expansion of its subsidiary Pharmaloop, to serve the rest of the world.
Currently, Salvat distributes its products in more than 60 countries and is in the process of registration in 30 more.
For the original news story, please visit https://prdistribution.com/news/laboratorios-salvat-leads-the-development-of-the-first-treatment-for-otomycosis.html.